Valsartan addition to amlodipine is more effective than losartan addition in hypertensive patients inadequately controlled by amlodipine

Roberto Fogari, Amedeo Mugellini, Paola Preti, Annalisa Zoppi, Giuseppe Derosa

Research output: Contribution to journalArticle


Introduction: This study evaluated the effects on blood pressure (BP) of valsartan 160 mg or losartan 100 mg addition to amlodipine 5 mg in hypertensive patients. Methods: 221 patients with inadequately controlled BP (DBP ≥ 90 mmHg) after 4 weeks of treatment with amlodipine 5 mg were randomized to receive losartan/amlodipine combination therapy or valsartan/amlodipine combination therapy for 4 weeks in a cross-over study design. At the end of the wash-out period and of each treatment period, clinic and ambulatory BP measurements were recorded. Results: 166 patients completed the study. Both combination treatments induced a greater ambulatory BP reduction than did monotherapy. However, the further mean reductions in BP versus monotherapy were significantly greater with the valsartan/amlodipine combination (SBP/DBP: -7.9 ± 3.4/-6.5 ± 2.6 mmHg for 24-hour, -8.0 ± 3.4/-6.6 ± 2.7 mmHg for daytime; -7.7 ± 3.3/-6.4 ± 2.7 m mHg for nighttime) than with the losartan/amlodipine combination (SBP/DBP: -5.5 ± 2.8/-4.2 ± 2.1 mmHg for 24-hour, -5.7 ± 2.9/-4.4 ± 2.2 mmHg for daytime; -4.8 ± 2.8/-3.7 ± 2.2 mmHg for nighttime; P <0.01 vs valsartan/amlodipine). The incidence of adverse events with valsartan/amlodipine (8%) and losartan/amlodipine (9%) was lower than that observed with amlodipine monotherapy (17%; P <0.05 vs combinations). Conclusion: Valsartan 160 mg plus amlodipine 5 mg produced greater BP reductions than losartan 100 mg plus amlodipine 5 mg.

Original languageEnglish
Pages (from-to)87-93
Number of pages7
JournalVascular Health and Risk Management
Issue number1
Publication statusPublished - 2010



  • Ambulatory blood pressure monitoring
  • Amlodipine
  • Angiotensin receptor blocker
  • Combination therapy
  • Losartan
  • Valsartan

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Endocrinology, Diabetes and Metabolism
  • Hematology
  • Pharmacology (medical)
  • Public Health, Environmental and Occupational Health

Cite this